Hikal Q2FY27: revenue at Rs 434 crores, loss narrows to Rs (6) crores; full-year guidance reiterated
Q2FY27 revenue Rs 434 crores against Rs 319 crores a year ago; EBITDA Rs 45 crores; loss narrowed to Rs (6) crores from Rs (35) crores.
By ScoutQuest · · 1 min read
- Q2FY27 revenue
- Rs 434 crores against Rs 319 crores a year ago
- EBITDA
- Rs 45 crores at a 10.3% margin versus 2.3% a year earlier
- PAT
- loss of Rs (6) crores against a loss of Rs (35) crores
- Period
- Q2 FY27, quarter ended Sep 30, 2026
- Positioning
- Hikal presents itself as a 5-facility, 3,000+ employee manufacturer of APIs, advanced intermediates and crop-protection actives, with pharmaceuticals at 64% of Q2FY27 consolidated revenue and crop protection at 36%.
📉 Consolidated revenue for Q2FY27 was Rs 434 crores against Rs 319 crores in Q2FY26, with EBITDA of Rs 45 crores at a 10.3% margin versus 2.3% a year earlier; PAT was a loss of Rs (6) crores against a loss of Rs (35) crores, so the quarter was still loss-making despite the narrowing, and EPS was Rs (0.49).
📉 Pharmaceuticals rose to 64% of consolidated revenue in Q2FY27 from 59% a year earlier, while Crop-Protection fell to 36% from 41%; the company attributes the pharma recovery to the established API portfolio, pricing and new-product commercialisation, and says Animal Health grew year on year.
💰 The full-year picture is weaker: FY26 consolidated revenue was Rs 1,713 crores, EBITDA Rs 220 crores and PAT Rs 5 crores, each below the FY25 level shown on the same slide, and the ratios page shows FY26 ROE at 3.00% with net debt/EBITDA at 2.90x.
🌍 Management states it expects business to improve in H2 on API recovery, CDMO pipeline conversion and better agrochemical CDMO demand, and points to a signed multi-year CDMO contract with a Europe-based agrochemical company, the start of Personal Care production at Panoli and Swissmedic GMP clearance for the Bengaluru API site.
Also from Hikal
Hikal Ltd press release, Q2 FY27
3 Nov 2026
Board names three executives authorised to decide materiality of events and disclose them to exchanges
3 Nov 2026
Standalone results for the quarter ended 30-Sep-26
3 Nov 2026
More numbers
- Revenue, Q2FY27434 (Rs. In Crs)
- EBITDA, Q2FY2745 (Rs. In Crs)
- PAT, Q2FY27(6) (Rs. In Crs)
- EBITDA margin, Q2FY2710.3%
- Revenue, Q2FY26319 (Rs. In Crs)
- PAT, Q2FY26(35) (Rs. In Crs)
- EBITDA margin, Q2FY262.3%
- Pharmaceuticals share of revenue, Q2FY2764%
- Revenue, FY261,713 (Rs. In crores)
- EBITDA, FY26220 (Rs. In crores)
- PAT, FY265 (Rs. In crores)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.